Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBITDA (2022 - 2025)

Stoke Therapeutics has reported EBITDA over the past 4 years, most recently at -$57.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 435.58% year-over-year to -$57.8 million; the TTM value through Dec 2025 reached -$6.2 million, up 93.05%, while the annual FY2025 figure was -$6.2 million, 93.05% up from the prior year.
  • EBITDA for Q4 2025 was -$57.8 million at Stoke Therapeutics, down from -$38.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $112.9 million in Q1 2025 and troughed at -$57.8 million in Q4 2025.
  • A 4-year average of -$18.8 million and a median of -$25.5 million in 2022 define the central range for EBITDA.
  • On a YoY basis, EBITDA climbed as much as 528.56% in 2025 and fell as far as 435.58% in 2025.
  • Year by year, EBITDA stood at -$25.1 million in 2022, then dropped by 6.8% to -$26.8 million in 2023, then surged by 59.76% to -$10.8 million in 2024, then crashed by 435.58% to -$57.8 million in 2025.
  • Business Quant data shows EBITDA for STOK at -$57.8 million in Q4 2025, -$38.0 million in Q3 2025, and -$23.3 million in Q2 2025.